Alkermes ALKS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Aristada And Aristada Initio | $93.82M+27.7% | $97.22M+0.6% | $98.05M+15.8% | $101.3M+17.7% | $73.48M-6.8% | |
| LUMRYZ | $39.49M— | —— | —— | —— | —— | |
| LYBALVI | $92.36M+31.9% | $94.14M+22.3% | $98.25M+31.5% | $84.28M+18.1% | $70.02M+22.8% | |
| Vivitrol | $112.43M+11.3% | $124.13M-7.5% | $121.13M+6.6% | $121.66M+8.7% | $101M+3.4% | |
| Accrued Sales Discounts Allowances And Reserves by Product | ||||||
| Medicaid Rebate | $189.03M-1.3% | $186.07M-7.9% | $191.43M-14.2% | $189.02M-11.3% | $191.47M-2.7% | |
| Medicare Part D | $25.49M+11.3% | $25.37M-5.8% | $18.82M-21.8% | $23.91M+31.1% | $22.89M+46.1% | |
| Other | $39.62M+97.3% | $17M-29.5% | $24.78M+27.7% | $23.41M+46.2% | $20.08M+46.0% | |
| Product Discounts | $18.7M+21.8% | $18.69M-3.4% | $17.71M+14.1% | $16.83M+3.9% | $15.35M+4.5% | |
| Actual Credits Received Related To Duplicate Billings by Product | ||||||
| Aristada And Aristada Initio | $2.8M— | $13.6M— | $12.1M— | $7.2M— | —— | |
| LYBALVI | $500K— | —— | —— | —— | —— | |
| Vivitrol | $5.4M— | $26.7M— | $25.3M— | $17.7M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
